Category Archives: Business and Investments

Latest From Business and Investments

Q&A with Complete Genomics’ Dr. Clifford Reid

Read a recent interview with Complete Genomics Chairman, President, and CEO Clifford Reid about his company’s top priorities, what makes his company attractive to investors, and what he hopes to accomplish at the 8th Annual BIO Investor Forum.  Complete Genomics sequenced its first genome in early 2009 and that data is publically available in the National Center for Biotechnology Information (NCBI) database. Already, in 2009, Complete Genomics has sequenced and delivered genomes to important collaborators Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

A BIO Investor Forum Success Story

A year ago, CombinatoRx probably wouldn’t have guessed a multi-million dollar merger was on the horizon.  However, after crossing paths with Neuromed at the 2008 BIO Investor Forum, the company found itself en-route to a July 2009 announcement of a $30 million dollar merger.   The deal is expected to close this quarter. Read the full story at TheDeal.com.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Podcast with Debra Miller, Cure Duchenne

Biotech-Now’s Tracy Krughoff spoke with Cure Duchenne’s President, Debra Miller. Cure Duchenne will be one of the patient advocacy organizations presenting at the Eighth Annual BIO Investor Forum next week. Listen Now!

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novavax launches study of novel H1N1 vaccine in Mexico

Novavax, Inc. (Nasdaq: NVAX) initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Clinical trial results for Calistoga Pharmaceuticals’ CAL-101

Calistoga Pharmaceuticals, Inc., announced interim results from the ongoing Phase 1 trial evaluating CAL-101, a PI3K inhibitor, showing promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At this interim assessment, 29 percent of CLL patients treated in the cohort expansion dose levels had partial responses observed after 28 days of therapy (1 cycle) and 94 percent have achieved evidence of biologic activity with a greater than 50 percent decrease in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,